Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
Vericel (NASDAQ:VCEL) reported strong financial results for Q4 and full-year 2024. The company achieved 20% total revenue growth to $237.2 million for the full year, with MACI revenue up 20% to $197.3 million and Burn Care revenue growing 22% to $39.9 million.
Q4 highlights include total net revenue of $75.4 million, record gross margin of 78%, and net income of $19.8 million. The company reported strong MACI Arthro launch indicators with approximately 250 surgeons trained. Cash position stands at $167 million with no debt.
For 2025, Vericel projects revenue growth of 20-23%, with gross margin expected at 73-74%. The company also updated its mid-term profitability targets, expecting gross margin in the high-70% range and adjusted EBITDA margin in the high-30% range by 2029.
Vericel (NASDAQ:VCEL) ha riportato risultati finanziari solidi per il quarto trimestre e per l'intero anno 2024. L'azienda ha raggiunto una crescita del fatturato totale del 20%, arrivando a 237,2 milioni di dollari per l'intero anno, con i ricavi da MACI in aumento del 20% a 197,3 milioni di dollari e i ricavi da Burn Care in crescita del 22% a 39,9 milioni di dollari.
I punti salienti del quarto trimestre includono un fatturato netto totale di 75,4 milioni di dollari, un margine lordo record del 78% e un reddito netto di 19,8 milioni di dollari. L'azienda ha riportato indicatori di lancio forti per MACI Arthro, con circa 250 chirurghi formati. La posizione di cassa è di 167 milioni di dollari senza debiti.
Per il 2025, Vericel prevede una crescita del fatturato del 20-23%, con un margine lordo previsto tra il 73% e il 74%. L'azienda ha anche aggiornato i suoi obiettivi di redditività a medio termine, prevedendo un margine lordo nella fascia alta del 70% e un margine EBITDA rettificato nella fascia alta del 30% entro il 2029.
Vericel (NASDAQ:VCEL) reportó resultados financieros sólidos para el cuarto trimestre y el año completo 2024. La compañía logró un crecimiento del 20% en ingresos totales, alcanzando los 237.2 millones de dólares para el año completo, con ingresos de MACI en aumento del 20% a 197.3 millones de dólares y ingresos de Burn Care creciendo un 22% a 39.9 millones de dólares.
Los aspectos destacados del cuarto trimestre incluyen ingresos netos totales de 75.4 millones de dólares, un margen bruto récord del 78% y un ingreso neto de 19.8 millones de dólares. La compañía reportó indicadores de lanzamiento fuerte para MACI Arthro, con aproximadamente 250 cirujanos capacitados. La posición de efectivo es de 167 millones de dólares sin deudas.
Para 2025, Vericel proyecta un crecimiento de ingresos del 20-23%, con un margen bruto esperado del 73-74%. La compañía también actualizó sus objetivos de rentabilidad a medio plazo, esperando un margen bruto en el rango alto del 70% y un margen EBITDA ajustado en el rango alto del 30% para 2029.
Vericel (NASDAQ:VCEL)는 2024년 4분기 및 전체 연도에 대한 강력한 재무 결과를 보고했습니다. 이 회사는 총 수익 20% 성장을 달성하여 전체 연도에 2억 3,720만 달러에 도달했으며, MACI 수익은 20% 증가하여 1억 9,730만 달러, Burn Care 수익은 22% 증가하여 3,990만 달러에 이르렀습니다.
4분기 하이라이트에는 총 순수익 7,540만 달러, 기록적인 총 이익률 78%, 순이익 1,980만 달러가 포함됩니다. 이 회사는 약 250명의 외과의사가 훈련된 MACI Arthro 출시 지표를 보고했습니다. 현금 보유액은 1억 6,700만 달러로 부채가 없습니다.
2025년을 위해 Vericel은 20-23%의 수익 성장을 예상하고 있으며, 총 이익률은 73-74%로 예상하고 있습니다. 이 회사는 또한 중기 수익성 목표를 업데이트하여 2029년까지 총 이익률이 70% 중반, 조정된 EBITDA 마진이 30% 중반에 이를 것으로 예상하고 있습니다.
Vericel (NASDAQ:VCEL) a annoncé des résultats financiers solides pour le quatrième trimestre et l'année entière 2024. L'entreprise a réalisé une croissance du chiffre d'affaires total de 20%, atteignant 237,2 millions de dollars pour l'année entière, avec des revenus MACI en hausse de 20% à 197,3 millions de dollars et des revenus de Burn Care en hausse de 22% à 39,9 millions de dollars.
Les points forts du quatrième trimestre incluent un chiffre d'affaires net total de 75,4 millions de dollars, une marge brute record de 78% et un revenu net de 19,8 millions de dollars. L'entreprise a signalé de solides indicateurs de lancement pour MACI Arthro, avec environ 250 chirurgiens formés. La position de trésorerie s'élève à 167 millions de dollars sans dettes.
Pour 2025, Vericel prévoit une croissance du chiffre d'affaires de 20 à 23%, avec une marge brute attendue entre 73% et 74%. L'entreprise a également mis à jour ses objectifs de rentabilité à moyen terme, s'attendant à une marge brute dans la fourchette haute des 70% et une marge EBITDA ajustée dans la fourchette haute des 30% d'ici 2029.
Vericel (NASDAQ:VCEL) hat starke finanzielle Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 berichtet. Das Unternehmen erzielte ein Umsatzwachstum von 20% auf 237,2 Millionen US-Dollar für das gesamte Jahr, wobei die MACI-Umsätze um 20% auf 197,3 Millionen US-Dollar und die Burn Care-Umsätze um 22% auf 39,9 Millionen US-Dollar stiegen.
Zu den Höhepunkten des vierten Quartals gehören ein Nettoumsatz von 75,4 Millionen US-Dollar, eine Rekord-Bruttomarge von 78% und ein Nettogewinn von 19,8 Millionen US-Dollar. Das Unternehmen berichtete von starken Startindikatoren für MACI Arthro, mit etwa 250 ausgebildeten Chirurgen. Die Liquiditätsposition beträgt 167 Millionen US-Dollar ohne Schulden.
Für 2025 prognostiziert Vericel ein Umsatzwachstum von 20-23%, wobei die Bruttomarge voraussichtlich bei 73-74% liegen wird. Das Unternehmen hat auch seine mittelfristigen Rentabilitätsziele aktualisiert und erwartet, dass die Bruttomarge bis 2029 im hohen 70%-Bereich und die bereinigte EBITDA-Marge im hohen 30%-Bereich liegen wird.
- Record Q4 gross margin of 78%, up 300 basis points YoY
- Q4 net income up 52% to $19.8 million
- Full-year revenue growth of 20% to $237.2M
- Strong cash position of $167M with no debt
- Adjusted EBITDA grew 58% to $53.4M in 2024
- Q4 operating cash flow of $22.2M
- Operating expenses increased due to higher headcount and marketing costs
- Epicel revenue declined in Q4 2024 ($6.0M) compared to Q4 2023 ($7.8M)
Insights
Vericel delivered exceptional Q4 and full-year 2024 results that demonstrate the company's strengthening market position in advanced cell therapies. The 20% annual revenue growth to
What's particularly impressive is Vericel's margin expansion story. The record Q4 gross margin of
The MACI Arthro launch appears to be gaining significant traction. With approximately 250 surgeons trained, the company is efficiently expanding its addressable market beyond knee cartilage repair into shoulder applications. This expansion effectively leverages their existing commercial infrastructure and manufacturing capabilities.
Vericel's strong cash position of
Management's raised mid-term profitability targets – with gross margins expected to reach the high-70% range and adjusted EBITDA margins in the high-30% range by 2029 – signal confidence in their ability to continue scaling efficiently. The 2025 guidance of
Vericel's 2024 results validate its leadership position in the advanced cell therapy market, with technology platforms that continue to demonstrate strong clinical adoption and expanding applications. The
The MACI Arthro launch represents a significant technological achievement in adapting their autologous chondrocyte implantation platform to the complex anatomy of the shoulder. Unlike the knee, which has relatively flat cartilage surfaces, the glenohumeral joint presents unique challenges for cartilage restoration. The training of approximately 250 surgeons in such a short period is remarkable – representing roughly
The burn care franchise shows interesting dynamics. While Epicel remains the foundation with
Vericel's new manufacturing facility represents a strategic investment in their future capacity needs. Cell therapy manufacturing requires specialized cleanroom environments and rigorous quality systems. This expansion will not only support growing demand but likely enable production efficiencies through increased scale and automation, further enhancing their impressive margin profile.
The planned MACI Ankle IND submission highlights Vericel's systematic approach to expanding their cartilage repair platform to additional high-value indications. Ankle cartilage defects present a significant unmet need with effective treatment options, particularly for talar dome lesions that often affect younger, active patients.
The international expansion initiative could substantially increase Vericel's addressable market, though they'll need to navigate different reimbursement environments and regulatory pathways for these specialized cell therapies.
Full-Year Total Revenue Growth of
Full-Year Adjusted EBITDA Growth of
Record Fourth Quarter Gross Margin of
Mid-Term Profitability Targets Increased to Gross Margin in the High
Strong MACI Arthro Key Launch Indicators, with Approximately 250 MACI Arthro Surgeons Trained to Date
2025 Financial Guidance with Total Revenue Growth of
Conference Call Today at 8:30am Eastern Time
CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2024.
Fourth Quarter 2024 Financial Highlights
- Total net revenue of
$75.4 million - MACI® net revenue of
$68.3 million , representing21% growth versus the prior year and53% growth versus the prior quarter - Burn Care net revenue of
$7.0 million , consisting of$6.0 million of Epicel® revenue and$1.0 million of NexoBrid® revenue - Gross margin of
78% , an increase of approximately 300 basis points versus the prior year - Net income growth of
52% to$19.8 million , or$0.38 per diluted share - Non-GAAP adjusted EBITDA increased
34% to$29.9 million , representing adjusted EBITDA margin of40% , an increase of approximately 530 basis points versus the prior year - Operating cash flow of
$22.2 million - As of December 31, 2024, the Company had approximately
$167 million in cash, restricted cash and investments, and no debt
Full-Year 2024 Financial Highlights
- Total net revenue increased
20% to$237.2 million - MACI net revenue growth of
20% to$197.3 million - Burn Care net revenue growth of
22% to$39.9 million , consisting of$36.6 million of Epicel revenue and$3.3 million of NexoBrid revenue - Gross margin of
73% , an increase of approximately 390 basis points versus the prior year - Net income of
$10.4 million , or$0.20 per diluted share - Non-GAAP adjusted EBITDA of
$53.4 million , representing adjusted EBITDA margin of23% , an increase of approximately 540 basis points versus the prior year - Operating cash flow of
$58.2 million
Fourth Quarter Business Highlights and Updates
- Highest number of MACI implants, implanting surgeons, surgeons taking biopsies and MACI biopsies in a quarter since launch
- Approximately 250 MACI Arthro™ surgeons trained to date
- NexoBrid hospital orders in the fourth quarter increased
42% versus the prior quarter - Completed construction of new corporate headquarters and manufacturing facility and remain on track to initiate commercial manufacturing in the facility in 2026
- Initiated assessment of opportunities to commercialize MACI outside the U.S.
- On track to submit MACI Ankle™ IND in the first half of 2025 and expect to initiate clinical study in second half of 2025
“The Company executed extremely well in 2024, delivering high revenue growth across both franchises and very strong margin expansion and profitability,” said Nick Colangelo, President and CEO of Vericel. “We are entering 2025 with a great deal of momentum and expect another year of high revenue growth and significant growth in profitability and cash generation driven by the strength in our core portfolio and increasing utilization of MACI Arthro.”
2025 Financial Guidance
- Total net revenue growth expected to be
20% to23% - Gross margin expected to be
73% to74% - Adjusted EBITDA margin expected to be
25% to26%
Mid-Term Profitability Targets
- Gross margin is expected to increase to the high
-70% range by 2029 - Adjusted EBITDA margin expected to increase to the high
-30% range by 2029
Fourth Quarter 2024 Results
Total net revenue for the quarter ended December 31, 2024 increased
Gross profit for the quarter ended December 31, 2024 was
Total operating expenses for the quarter ended December 31, 2024 were
Net income for the quarter ended December 31, 2024 was
Non-GAAP adjusted EBITDA for the quarter ended December 31, 2024 was
As of December 31, 2024, the Company had approximately
Full-Year 2024 Results
Total net revenue for the year ended December 31, 2024 increased
Gross profit for the year ended December 31, 2024 was
Total operating expenses for the year ended December 31, 2024 were
Net income for the year ended December 31, 2024 was
Non-GAAP adjusted EBITDA for the year ended December 31, 2024 was
Conference Call Information
Today’s conference call will be available live at 8:30am Eastern Time and can be accessed through the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. A slide presentation with highlights from today’s conference call will be available on the webcast and in the Investor Relations section of the Vericel website. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software, if necessary. To participate by telephone, please register here to receive dial-in details and your personal passcode. A replay of the webcast will be available on the Vericel website until February 26, 2026.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2025 Vericel Corporation. All rights reserved.
GAAP v. Non-GAAP Measures
Vericel’s reported earnings are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the Securities and Exchange Commission. Vericel has provided in this release certain financial information that has not been prepared in accordance with GAAP. Vericel’s management believes that the non-GAAP adjusted EBITDA described in this release, which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding Vericel’s underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in Vericel’s industry. However, the non-GAAP financial measures that Vericel uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.
Forward-Looking Statements
Vericel cautions you that all statements other than statements of historical fact included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Our actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.
Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with our expectations regarding future revenue, growth in revenue, market penetration for MACI, MACI Arthro, Epicel, and NexoBrid, growth in profit, gross margins and operating margins, the ability to continue to scale our manufacturing operations to meet the demand for our cell therapy products, including the timely qualification of a new manufacturing facility in Burlington, Massachusetts, the ability to sustain profitability, contributions to adjusted EBITDA, the expected target surgeon audience, potential fluctuations in sales and volumes and our results of operations over the course of the year, timing and conduct of clinical trial and product development activities, timing and likelihood of the FDA’s potential approval of the use of MACI to treat cartilage defects in the ankle, the estimate of the commercial growth potential of our products and product candidates, competitive developments, changes in third-party coverage and reimbursement, surgeon adoption of MACI Arthro, physician and burn center adoption of NexoBrid, labor strikes, changes in surgeon and hospital treatment prioritizations caused by the temporary shortage of essential medical supplies, supply chain disruptions or other events or factors that might affect our ability to manufacture MACI or Epicel or affect MediWound’s ability to manufacture and supply sufficient quantities of NexoBrid to meet customer demand, including but not limited to, damage or disruption caused by natural disasters and the ongoing conflicts in the Middle East region involving Israel, negative impacts on the global economy and capital markets resulting from the conflict in Ukraine and the Middle East conflicts, changes in trade policies and regulations, including the potential for increases or changes in duties, current and potentially new tariffs or quotas, lingering effects of adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, possible changes in governmental monetary and fiscal policies, including, but not limited to, Federal Reserve policies in connection with continued inflationary pressures and the impact of the recent elections in the United States, global geopolitical tensions and potential future impacts on our business or the economy generally stemming from a public health emergency.
These and other significant factors are discussed in greater detail in Vericel’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025 and in other filings with the SEC. These forward-looking statements reflect our views as of the date hereof and Vericel does not assume and specifically disclaims any obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release except as required by law.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
| VERICEL CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts - unaudited) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Product sales, net | $ | 75,376 | $ | 64,996 | $ | 237,224 | $ | 197,516 | |||||||
| Total revenue | 75,376 | 64,996 | 237,224 | 197,516 | |||||||||||
| Cost of product sales | 16,877 | 16,489 | 65,117 | 61,940 | |||||||||||
| Gross profit | 58,499 | 48,507 | 172,107 | 135,576 | |||||||||||
| Research and development | 4,923 | 4,901 | 24,797 | 21,042 | |||||||||||
| Selling, general and administrative | 35,097 | 30,875 | 142,791 | 120,998 | |||||||||||
| Total operating expenses | 40,020 | 35,776 | 167,588 | 142,040 | |||||||||||
| Income (loss) from operations | 18,479 | 12,731 | 4,519 | (6,464 | ) | ||||||||||
| Other income (expense): | |||||||||||||||
| Interest income | 1,560 | 1,436 | 6,410 | 4,632 | |||||||||||
| Interest expense | (154 | ) | (156 | ) | (614 | ) | (600 | ) | |||||||
| Other income | 70 | 82 | 195 | 64 | |||||||||||
| Total other income | 1,476 | 1,362 | 5,991 | 4,096 | |||||||||||
| Income (loss) before income taxes | 19,955 | 14,093 | 10,510 | (2,368 | ) | ||||||||||
| Income tax expense | 148 | 1,100 | 148 | 814 | |||||||||||
| Net income (loss) | $ | 19,807 | $ | 12,993 | $ | 10,362 | $ | (3,182 | ) | ||||||
| Net income (loss) per common share: | |||||||||||||||
| Basic | $ | 0.40 | $ | 0.27 | $ | 0.21 | $ | (0.07 | ) | ||||||
| Diluted | $ | 0.38 | $ | 0.26 | $ | 0.20 | $ | (0.07 | ) | ||||||
| Weighted-average common shares outstanding: | |||||||||||||||
| Basic | 49,469 | 47,745 | 48,848 | 47,590 | |||||||||||
| Diluted | 52,210 | 50,512 | 51,679 | 47,590 | |||||||||||
| VERICEL CORPORATION RECONCILIATION OF REPORTED NET INCOME (LOSS) (GAAP) TO ADJUSTED EBITDA (NON-GAAP MEASURE) (in thousands - unaudited) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net income (loss) | $ | 19,807 | $ | 12,993 | $ | 10,362 | $ | (3,182 | ) | ||||||
| Stock-based compensation expense | 7,917 | 6,909 | 36,495 | 32,325 | |||||||||||
| Depreciation and amortization | 1,477 | 1,149 | 5,504 | 4,632 | |||||||||||
| Net interest income | (1,406 | ) | (1,280 | ) | (5,796 | ) | (4,032 | ) | |||||||
| Income tax expense | 148 | 1,100 | 148 | 814 | |||||||||||
| Pre-occupancy lease expense | 1,924 | 1,424 | 6,725 | 3,323 | |||||||||||
| Adjusted EBITDA (Non-GAAP) | $ | 29,867 | $ | 22,295 | $ | 53,438 | $ | 33,880 | |||||||
| VERICEL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands - unaudited) | |||||||
| December 31, | |||||||
| 2024 | 2023 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 74,520 | $ | 69,088 | |||
| Restricted cash | 10,529 | 17,778 | |||||
| Short-term investments | 41,693 | 40,469 | |||||
| Accounts receivable (net of allowance for doubtful accounts of | 61,375 | 58,356 | |||||
| Inventory | 17,373 | 13,087 | |||||
| Other current assets | 7,287 | 6,853 | |||||
| Total current assets | 212,777 | 205,631 | |||||
| Property and equipment, net | 103,161 | 41,635 | |||||
| Intangible assets, net | 6,250 | 6,875 | |||||
| Right-of-use assets | 70,098 | 73,462 | |||||
| Long-term investments | 39,880 | 25,283 | |||||
| Other long-term assets | 556 | 771 | |||||
| Total assets | $ | 432,722 | $ | 353,657 | |||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 23,848 | $ | 22,347 | |||
| Accrued expenses | 17,065 | 17,215 | |||||
| Current portion of operating lease liabilities | 9,257 | 6,187 | |||||
| Other current liabilities | 116 | — | |||||
| Total current liabilities | 50,286 | 45,749 | |||||
| Operating lease liabilities | 89,593 | 81,856 | |||||
| Other long-term liabilities | 876 | 100 | |||||
| Total liabilities | 140,755 | 127,705 | |||||
| Total shareholders’ equity | 291,967 | 225,952 | |||||
| Total liabilities and shareholders’ equity | $ | 432,722 | $ | 353,657 | |||
FAQ
What was Vericel's (VCEL) revenue growth in 2024?
How much cash does Vericel (VCEL) have as of December 2024?
What are Vericel's (VCEL) financial projections for 2025?
What was Vericel's (VCEL) Q4 2024 performance?
How many surgeons are trained for MACI Arthro procedures at Vericel (VCEL)?
